Prog Neuropsychopharmacol Biol Psychiatry 21, 69-102, (1997) Maurice, T., & Lockhart, B. P. View abstract in PubMed Post navigationPreviousPrevious post:Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.NextNext post:SA4503, a novel cognitive enhancer with sigma1receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.Related PostsAnavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental DisordersNovember 30, 2020Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceNovember 25, 2020Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental DisordersNovember 30, 2020
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceNovember 25, 2020
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020
